About
Walden is taking a bold, innovative, and targeted approach to developing disease-modifying therapies for kidney disease
As a clinical-stage biotech company, Walden’s mission to transform the treatment of kidney disease starts with a new approach: treating the disease itself and not just the underlying symptoms. We accomplish this by developing a deep understanding of the drivers of kidney disease and use these insights to develop breakthrough, disease-modifying medicines that selectively target the kidney. Walden has the people, the pipeline, and the passion to truly change the treatment landscape for kidney diseases and help the 700+ million patients around the world battling these degenerative diseases.
Management
Managed by an exceptional leadership team
Board of Directors
Backed and advised by renowned venture capital investors
